Tirzepatide

Also known as: Mounjaro, Zepbound

Weight LossFDA APPROVED

Clinical Status

FDA Approved — Type 2 diabetes, chronic weight management.

Mechanism of Action

Activates both GLP-1 and GIP receptors, providing synergistic effects on appetite suppression, insulin secretion, and metabolic regulation.

Dosing Defaults

Dose

5-15 mg weekly

Frequency

Once weekly

Administration

Subcutaneous injection weekly

Timing

Morning, same day each week

Food

with or without

Duration

Long-term / chronic use

Dose range: 2.5-15 mg weekly

Weekly injection — consistency of day matters more than time of day.

Side Effects

•Nausea
•Diarrhea
•Vomiting
•Constipation
•Decreased appetite
•Abdominal pain
•Pancreatitis
•Gallbladder problems

Contraindications & Warnings

⚠Personal/family history of medullary thyroid carcinoma
⚠MEN 2 syndrome

•Not medical advice
•BOXED WARNING: Thyroid C-cell tumors

Compare

Compare Tirzepatide with another peptide side-by-side.

Calculate Dose

Use the reconstitution calculator to prepare your Tirzepatide dose.

Open Calculator

Related Weight Loss Peptides

Semaglutide

FDA APPROVED

Weight Loss

GLP-1 receptor agonist. FDA-approved for type 2 diabetes and weight management.

Retatrutide

PHASE 3

Weight Loss

Triple receptor agonist (GLP-1/GIP/Glucagon). Most potent weight loss peptide in trials.

AOD-9604

PHASE 2

Weight Loss

GH fragment for fat metabolism. Does NOT produce typical HGH side effects.

Liraglutide

FDA APPROVED

Weight Loss

Daily GLP-1 agonist. FDA-approved for both diabetes and weight management.

This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.